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A B S T R A C T
Adolescence is a pivotal period of brain development during lifespan, which is sensitive to stress exposure. Early
social isolation stress (SIS) is known to provoke a variety of psychiatric comorbidities as well as seizure risk.
Psychiatric comorbidities present challenging dilemmas for treatment and management in people with seizure
disorders. In this study, we aimed to investigate whether gabapentin (GBP) as an anti-epileptic drug is able to
alleviate the seizure activity as well as comorbid behavioral abnormalities in socially isolated mice. Results
showed that early SIS induced proconvulsant eﬀects along with depressive, aggressive and anxiety-like
behaviors. Whereas the administration of both acute and chronic GBP at sub-eﬀective doses produced no
alterations in the behavioral proﬁle of socially conditioned counterparts the same treatments eﬀectively reversed
the seizure susceptibility to pentylenetetrazole and behavioral deﬁcits in isolated mice. Results of the study
indicate that 1) Early SIS could be considered as an animal model of psychosocial stress to investigate the
psychiatric comorbidities in seizure disorders, 2) Chronic administration of low dose GBP prevented the
shaping of behavioral abnormalities in adulthood, 3) Chronic administration of low dose GBP produced no
negative behavioral eﬀects in socially conditioned mice suggesting the safety of the drug, 4) Gabapentin at low
doses may be considered as an agent for management of epilepsy in individuals with psychiatric comorbidities.
1. Introduction
The developing brain is susceptible to environmental inﬂuences and
exposure to stressful conditions profoundly aﬀects brain development
(Lupien et al., 2009). Adolescence is a pivotal state in cortico-limbic
development and is associated with maturation of behavioral and
cognitive abilities (Andersen and Teicher, 2008; Paus, 2005). Ample
evidence indicates that experiencing psychological stress during ado-
lescence potently predisposes the development of psychiatric diﬃcul-
ties in adulthood (Fone and Porkess, 2008). Evidence is accumulating
that epilepsy is associated with incidence of psychiatric disorders
(Kanner et al., 2012; Thapar et al., 2009). Psychiatric comorbidities
in seizure disorders are accompanied by notable burden in morbidity,
management of patients, treatment and quality of life (Fazel et al.,
2013; McCagh et al., 2009). Anxiety and depression are of most
prevalent psychiatric comorbidities which occur which occur 4–5 more
often in subjects with seizure disorders than in normal populations
(Maguire and Salpekar, 2013). Surprisingly, although there is a large
body of evidence indicating the importance of psychiatric comorbidity
in seizure disorders, fewer studies have focused on the treatment of
such comorbidities (Kanner, 2003; Swinkels et al., 2005).
Recently, we showed that early social isolation stress (SIS) pro-
voked seizure risk along with aﬀective behavioral dysfunctions in adult
mice (Amiri et al., 2014). Early life stress is known to increase the risk
of epileptogenesis and occurrence of psychiatric comorbidities (Huang,
2014; Jones et al., 2014). It has been suggested that applying animal
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models such as early SIS provides conditions to investigate the
psychopathological similarities which are observed in humans
(Nestler and Hyman, 2010).
There is a large body of evidence, which indicates that anti-epileptic
drugs have positive eﬀects on mood and behavior (Perucca and Mula,
2013; Russo et al., 2013). Gabapentin (GBP), as an anti-epileptic drug
with normothymic properties, is structurally similar to γ-aminobutyric
acid (GABA). Increasing lines of research suggest that GBP has
therapeutic eﬀects in mental disorders including mood and anxiety
disorders (Perucca and Mula, 2013). Gabapentin is known to reduce
the neural excitability in the central nervous system via binding to α2-δ
subunit of voltage-gated calcium channels leading to a decrease in
excitatory neurotransmission. Also, GBP has an ability to increase
ambient GABA levels in the brain indicating its eﬀects on alteration of
GABA synthesis or release (Brickley and Mody, 2012; Honmou et al.,
1995). However, the mechanism of action of GBP is not clear well
(Sills, 2006).
In this study, as early SIS induces proconvulsant eﬀects along with
aﬀective behaviors in mice, we aimed to investigate whether GBP is
able to attenuate the proconvulsant eﬀect of SIS along with psychiatric
comorbidities in male mice. GBP was used in this study because it is a
safe drug with minor side eﬀects and has a high therapeutic index (Arif
et al., 2009; Perucca and Mula, 2013).
2. Material and methods
2.1. Animals and housing conditions
Male NMRI mice weighing 10–12 g on postnatal day 21 (PND: 21)
(Pasteur Institute, Tehran, Iran) were used. Animals were housed
under standard conditions (temperature: 22 ± 2 °C, humidity: 50 ±
10%, 12-h light–dark cycle, and free access to food and water) for 4
weeks in two conditions: social condition (SC) and isolated condition
(IC). Socially conditioned mice were housed (6 per cage) in Plexiglas
cages (25 cm×25 cm ×15 cm) while IC mice were housed individually
in Plexiglas cages (24 cm×17 cm ×12 cm) in a separate room. Cages of
IC mice were cleaned weekly. All experiments were conducted during
the period between 09:00 a.m. and 02:00 p.m. Each experimental
group consisted of 6–8 mice. All procedures in this study were carried
out in accordance with the National Institutes of Health (NIH) Guide
for the Care and Use of Laboratory Animals (NIH publication # 80-23)
and institutional guidelines for animal care and use (Department of
Pharmacology, School of Medicine, TUMS).
2.2. Drug and treatment procedure
GBP was a gift from the Alborz Bulk pharmaceutical company, Iran.
Firstly, we determined the eﬀective and sub-eﬀective doses of GBP (in
both SC and IC mice) using pentylentetrazole (PTZ)-induced clonic
seizures paradigm. In order to investigate the acute eﬀects of GBP on
behavioral proﬁle of the mice, doses 1, 3, 5 mg/kg were injected 60 min
prior to the behavioral tests at PND: 50–54. GBP was freshly dissolved
in saline, being prepared immediately and administered intraperito-
neally (i.p.) with a volume of 5 ml/kg body weight.
In order to examine the chronic eﬀects of GBP on the behavioral
proﬁle of the mice various doses of GBP (1, 3, 5 mg/kg) were used after
1 week of housing (PND: 28). For this purpose, GBP dissolved in
drinking water and administered for 21 days (PND: 28–50). After the
treatment, experimental animals were subjected to behavioral tests at
PND: 50–54.
2.3. Open-ﬁeld test (OFT)
The open-ﬁeld test was used to evaluate the locomotion and anxiety
behavior (Kulesskaya and Voikar, 2014). The open-ﬁeld apparatus was
made of white opaque Plexiglas (50 cm×50 cm ×30 cm), which was
dimly illuminated. Each mouse was placed gently on the center square
(30 cm×30 cm), and behaviors were recorded by a camera for 5 min
and were analyzed by an experimenter blind to the treatments and
conditions. The surface of the apparatus was cleaned with 70% ethanol
after testing each mouse. The distance moved (horizontal activity), the
number of rearings (vertical activity) and also time spent in the central
zone were evaluated.
2.4. Hole-board test (HBT)
The hole-board test was used to evaluate the anxiety of subjects and
carried out based on our recent study (Amiri et al., 2015). The
apparatus consisted of a white Plexiglas square (50 cm×50 cm) with
16 equidistant holes (3 cm in diameter) and was positioned 50 cm
above the ﬂoor. Mice were placed in the center of the board and the
number of head-dips was counted in a 5-min period. The apparatus
was cleaned with 70% ethanol after testing each subject.
2.5. Elevated plus maze (EPM)
The EPM is an appropriate test to assess the eﬀects of both
anxiogenic and anxiolytic agents in rodents (Ducottet and Belzung,
2005). The apparatus was made of black opaque Plexiglas and
consisted of two open (30×5 cm) and closed (30×5×15 cm) arms,
which were connected by a platform area (5×5 cm). The testing room
was dimly illuminated and animals were individually placed in the
center of the EPM facing to closed arm and each behavioral session was
videotaped for a 5-min period. The total time spent in the open arms,
and number of entries into the open arms reported as percentages.
2.6. Forced swimming test (FST)
The test was directed using a method which was previously
described (Porsolt et al., 1977). In brief, mice were separately placed
in an open cylinder-shaped ﬂask (diameter: 10 cm, height: 25 cm),
containing 19 cm water at 23 ± 1 °C. Mice were permitted to swim for
6 min and the immobility time was recorded throughout the last 4 min
of the test. Each mouse was judged to be immobile when it ceased
struggling and stayed ﬂoating motionless in the water, making only
those movements necessary to keep its head above water.
2.7. Tail suspension test (TST)
The total duration of immobility induced by tail suspension was
measured based on the method described by Steru et al. (1985). Brieﬂy,
a mouse was suspended 50 cm above the bench by adhesive tape placed
1 cm from the tip of the tail. The mouse was considered immobile only
when it hung passively and completely motionless. Immobility time
was recorded during a 6-min period by an experimenter blind to the
animal condition.
2.8. Splash test
Splash test was carried out to evaluate the motivational and self-
care behaviors according a previously described method (Ducottet and
Belzung, 2004). In this test, grooming behavior of mice, which can be
considered as an indirect measure of palatable solution intake, was
measured. A 10% sucrose solution was squirted on the dorsal coat of
animals in their home cage and mice were videotaped for 5 min. The
total grooming activity time was recorded during 5 min after the
sucrose vaporization. Grooming activity consists of nose/face groom-
ing, head washing and body grooming.
2.9. Resident-intruder test
Evaluation of aggressive behavior was carried out according to a
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previously described method (Ibi et al., 2008; Ruzza et al., 2015). The
mice called “residents” were ﬁrst housed individually in transparent
plastic cages (24 cm×12 cm ×8 cm) for 5 days. To cause the aggressive
encounter, the “intruder”mouse was placed inside the home cage of the
resident mouse and behaviors of the resident mouse against the
intruder were videotaped over 5 min with a camera positioned above
the testing cage. The duration of aggressive behavior including attack-
ing/biting, tail rattling, aggressive grooming, sideways posturing and
pushing under were observed and analyzed by an experimenter blinded
to the treatment and housing conditions.
2.10. Determination of clonic seizure threshold
In order to measure the clonic seizure threshold in mice, we used a
method that was previously described in our studies (Amini-Khoei
et al., 2015a, 2015b). Brieﬂy, a winged infusion set (30 gauge) was used
to infuse the PTZ (0.5%) at a constant rate of 1 ml/min into the tail
vein of the freely moving subject. Infusion was halted when forelimb
clonus followed by full clonus of the body (began with running and then
loss of righting ability) was observed. The minimal dose of PTZ (mg/kg
mouse weight) needed to induce a clonic seizure was considered as the
index of seizure threshold. As such, seizure threshold is dependent on
the dose and time of PTZ administration.
2.11. Statistics
SPSS (version 21) and GraphPad prism (version 6.1) statistical
softwares were used for data analysis and ﬁgure creation. Comparisons
between the groups were assessed using t-test and one-way ANOVA
followed by Tukey's post hoc test. A value of P < 0.05 was considered
for signiﬁcance.
3. Results
3.1. Eﬀects of diﬀerent housing conditions and GBP treatments on the
seizure threshold dose of PTZ
As shown in Fig. 1A, t-test revealed that SIS signiﬁcantly decreased
the seizure threshold in comparison with SC mice (t=10.65 df=10, P <
0.001). Acute treatment with diﬀerent doses of GBP 60 min before the
test signiﬁcantly increased the seizure threshold in the PTZ-induced
seizure in SC and IC animals (F (7, 52) =14.831, P < 0.001, Fig. 1B).
The Tukey's post hoc test showed that acute injection of GBP
signiﬁcantly increased the seizure threshold in SC mice at doses 3
and 5 mg/kg (P < 0.05 and P < 0.001, respectively). Also, acute admin-
istration of GBP was eﬀective in the IC group only at a dose of 5 mg/kg
(P < 0.001) when compared to IC control counterpart. Fig. 1C shows
that chronic treatment with diﬀerent doses of GBP signiﬁcantly
increased the seizure threshold in SC and IC animals (F (7, 48)
=13.87, P < 0.01, Fig. 1C). Post test analysis showed that chronic
treatments with GBP had no signiﬁcant eﬀect on the seizure threshold
in SC mice, while a chronic dose of 5 mg/kg produced anticonvulsant
eﬀects in comparison with the IC control counterpart (P < 0.001).
3.2. Eﬀects of diﬀerent housing conditions and GBP treatments on the
number of head-dips in the hole-board test
One-way ANOVA analysis showed that there are signiﬁcant diﬀer-
ences between the groups in the number of head-dips in both the acute
and chronic scheduled experiments (F (7, 43) =25.7, Fig. 2A, P < 0.001,
F(7, 54) =12.3, P < 0.001, Fig. 2B). As shown, SIS signiﬁcantly
decreased the number of head dips in comparison to SC animals (P
< 0.001). Tukey's test showed that acute or chronic administration of
GBP 5 mg/kg signiﬁcantly increased the number of head dips of IC
mice when compared to IC control group (P < 0.001 for both).
However, administration of doses 1 and 3 mg/kg had no signiﬁcant
eﬀect in IC mice (P > 0.05). Furthermore, our results showed that there
are no signiﬁcant diﬀerences between acute and/or chronic GBP
treatment in SC mice when compared to control SC group (P > 0.05).
3.3. Eﬀects of diﬀerent housing conditions and GBP treatments on the
EPM
In the EPM, the percentage of time spent in the open arms and
percentage of open arms entries were evaluated as variables relevant to
anxiety-like behaviors. ANOVA analysis revealed that there are sig-
niﬁcant diﬀerences between the groups in the open arm time (F (7, 42)
=23.7, P < 0.001, Fig. 3A) for acute and (F (7, 47) =19.2, P < 0.001,
Fig. 3B) for chronic GBP treatment. One-way ANOVA revealed that
acute and/or chronic GBP treatment led to signiﬁcant diﬀerences in
open arm entries of SC and IC mice (F (7, 42) =25.7, P < 0.001, Fig. 3C)
for acute and (F (7, 47) =16.6, P < 0.001, Fig. 3D) for chronic
administration. In comparison with SC mice, SIS remarkably decreased
the percentage of time spent in the open arms (P < 0.01) as well as the
percentage of open arms entries (P < 0.001) in IC mice. Furthermore,
acute or chronic administration of GBP 5 mg/kg signiﬁcantly increased
the percentage of time spent in the open arms (P < 0.01) as well as the
percentage of open arms entries (P < 0.01) of IC mice when compared
to the IC control counterpart. The administration of doses 1 and 3 mg/
kg of GBP had no signiﬁcant eﬀect in the EPM of IC mice (P > 0.05).
Additionally, no signiﬁcant diﬀerence was observed in the EPM
between acute and/or chronic GBP treatment in SC mice when
compared to the control SC group (P > 0.05).
3.4. Eﬀects of the diﬀerent housing conditions and GBP treatments on
locomotion and anxiety-like behaviors in open ﬁeld test
Results obtained from one way ANOVA (Fig. 4) showed that there
are signiﬁcant diﬀerences in the time spent in the central zone (F (7,
46) =35.66, P < 0.001, Fig. 4A, acute treatment and F (7, 52) =43.17, P
< 0.001, Fig. 4B, chronic treatment), distance moved (horizontal
activity) (F (7, 46) =29.3, P < 0.001, Fig. 4C, acute treatment and F
(7, 52) =27.21, P < 0.001, Fig. 4D, chronic treatment) as well as the
number of rearings (vertical activity) (F (7, 46) =23.3, P < 0.001,
Fig. 4E, acute administration and F (7, 52) =17.06, P < 0.001,
Fig. 4F, chronic administration) in both acute and chronic treatment
with GBP. As shown in Fig. 4, isolation housing leads to a signiﬁcant
decrease in the time spent in central zone of OFT when compared to
the SC group (P < 0.001). In addition, GBP 1 and 3 mg/kg failed to
increase the central zone time spent of IC mice (P > 0.05). However,
administration of GBP 5 mg/kg increased the time spent in the central
zone for both acute and chronic treated groups (P < 0.001 for both).
Also, social isolation signiﬁcantly increased the distance moved (hor-
izontal activity) in IC mice in comparison with SC mice (P < 0.001).
Furthermore, treatment with GBP 5 mg/kg signiﬁcantly decreased the
horizontal activity in the both acute (P < 0.001) and chronic (P < 0.01)
treated IC groups when compared to the corresponding IC group.
However, GBP 1 and 3 mg/kg administrations had no eﬀect on this
behavior in IC animals (P > 0.05).
The isolation housing signiﬁcantly increased the number of rearing
in OFT when compared to the SC group (P < 0.001). As shown,
elevation in the number of rearings in the IC mice was signiﬁcantly
decreased after acute and chronic administration of GBP 5 mg/kg (P <
0.001 for acute and P < 0.01 chronic treatment). Additionally, treat-
ments with GBP 1 and 3 mg/kg had no eﬀect on the number of rearings
in either IC or SC group (P > 0.05). In addition, there are no signiﬁcant
diﬀerences among SC groups in the OFT (P > 0.05).
3.5. Eﬀects of the diﬀerent housing conditions and GBP treatments on
grooming activity time in the splash test
There are signiﬁcant diﬀerences in the grooming activity time in the
S. Amiri et al. European Journal of Pharmacology 797 (2017) 106–114
108
splash test in both the acute and chronic scheduled tests between IC
and SC groups (F (7, 50) =18, P < 0.001, Fig. 5A, acute treatment and F
(7, 48) =21.42, P < 0.001, Fig. 5B, chronic treatment). As shown in
Fig. 5, IC signiﬁcantly decreased the grooming activity time in
comparison to SC mice (P < 0.001). Tukey's test showed that grooming
activity time was signiﬁcantly increased by treatment with acute and
chronic GBP 5 mg/kg in IC mice compared to the IC control counter-
part (P < 0.001 and P < 0.01, respectively). Doses 1 and 3 mg/kg GBP
failed to create signiﬁcant grooming activity diﬀerences in IC mice (P >
0.05). In addition, there are no signiﬁcant diﬀerences among SC groups
(P > 0.05).
3.6. Eﬀects of the diﬀerent housing conditions and GBP treatments on
the aggressive behavior
Results of one-way ANOVA for resident-intruder test showed that
there are signiﬁcant diﬀerences in aggressive behavior in both acute
and chronic scheduled tests between IC and SC groups (F (7, 50) =27.2,
P < 0.001, Fig. 6A, acute treatment and F (7, 50) =40.80, P < 0.001,
Fig. 6B, chronic treatment). As shown, resident IC mice displayed a
higher duration of attack time against intruder mice than SC mice (P <
0.001). Moreover, administration of acute and chronic GBP 5 mg/kg
signiﬁcantly attenuated the duration of the attacks by IC mice in
comparison with IC control counterpart (P < 0.01 and P < 0.05, respec-
tively), whereas GBP 1 and 3 mg/kg either acute or chronic failed to
reduce this behavior (P > 0.05). Statistical analysis revealed that there
Fig. 1. Eﬀects of diﬀerent housing conditions (A), acute (B) and chronic (C) administration of GBP (1, 3 and 5 mg/kg, i.p.) on the seizure threshold in PTZ-induced convulsion). Values
are presented as mean ± S.E.M, n =7. *P < 0.05 and ***P < 0.001 compared to control SC mice, ###P < 0.001 compared to control IC mice.
Fig. 2. Eﬀects of diﬀerent housing conditions and also acute and chronic administration of GBP (1, 3 and 5 mg/kg) on the number of head-dips in the hole board test. Values are
expressed as the mean ± S.E.M, n=7. ***P < 0.001 compared to control SC group, ###P < 0.001 compared with the control IC group.
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are no signiﬁcant diﬀerences amongst control, acute and chronic
treatments in SC mice (P > 0.05).
3.7. Eﬀects of diﬀerent housing conditions and GBP treatments on the
immobility time in the FST and TST
ANOVA investigation demonstrated that there are signiﬁcant
diﬀerences between the groups in the immobility time of FST in GBP
treatments (acute and chronic) in two groups of animals (SC and IC) (F
(7, 48) =15.45, P < 0.001, Fig. 7A, acute treatment and F (7, 48)
=10.20, P < 0.001, Fig. 7B, chronic treatment). Findings showed that
SIS signiﬁcantly increased the immobility time in IC mice in compar-
ison with SC mice in the FST (P < 0.01). Tukey's test showed that
administration of acute (but not chronic treatment) GBP 5 mg/kg
signiﬁcantly decreased the immobility time in IC mice when compared
to IC control group (P < 0.05). However, administration of doses 1 and
3 mg/kg of GBP in acute as well as chronic regimen had no signiﬁcant
eﬀect on immobility time of FST in IC mice (P > 0.05). Furthermore, no
statistical signiﬁcant diﬀerences were seen in SC mice in the FST
between GBP groups with control counterpart (P > 0.05).
On the other hand, in TST there are signiﬁcant diﬀerences between
the groups in the immobility time in acute and chronic GBP treatments
SC and IC mice (F (7, 50) =121.1, P < 0.001, Fig. 8A, acute treatment
and F (7, 47) =173.3, P < 0.001, Fig. 8B, chronic treatment). Results
demonstrate that SIS signiﬁcantly increased immobility time in
comparison with social condition housing (P < 0.001). Tukey's test
showed that administration of acute (but not chronic) GBP 5 mg/kg
signiﬁcantly reduced the immobility time of IC animals when compared
to control IC counterpart (P < 0.001). However, administration of
lower doses in acute treatments and all applied doses of GBP in
chronic treatments had no signiﬁcant eﬀect in immobility time of IC
mice in the TST (P > 0.05). In addition, no signiﬁcances were observed
in SC mice between GBP and control mice (P > 0.05).
4. Discussion
In this study, we showed that early SIS provoked a variety of
behavioral abnormalities relevant to depression, anxiety and aggres-
siveness. In addition, behavioral alterations in adult IC mice correlated
with increased seizure susceptibility to PTZ. Results of this study also
demonstrated that administration of GBP (acute and chronic) reversed
the proconvulsant eﬀects of early SIS as well as psychiatric comorbid-
ities. However, the same treatment with GBP produced no behavioral
alteration in the social condition counterparts.
Adolescence is considered as a sensitive period of life of which
exposure to chronic stress in this period potently increases the risk of
psychiatric diﬃculties as well as seizure disorders in later life (Amiri
et al., 2014; Andersen and Teicher, 2008; Huang, 2014). Consistent
with previous studies, our results revealed that 28 days of SIS (PND:
21–49) exerted proconvulsant eﬀects along with psychiatric comorbid-
ities including depressive, aggressive and anxiety-like behaviors in IC
mice (Fone and Porkess, 2008; Matsumoto et al., 2003). It is well-
accepted that psychiatric comorbidities in people with seizure disorders
not only aﬀect the quality of life but also, complicate the drug therapy
(Maguire and Salpekar, 2013). Social environments such as social
isolation, play a key role in triggering the incidence of psychiatric
comorbidities in patients with epilepsy (McCagh et al., 2009). Our
results revealed that early SIS is able to induce co-occurrence of
psychiatric diﬃculties with seizure disorders suggesting that early SIS
is a useful animal model to investigate the underlying mechanisms
involved in psychiatric complications in seizure disorders.
Considering that depression is the most frequently occurring
comorbid psychiatric disorder in patients with epilepsy, we showed
that IC mice exhibited behaviors related to core symptoms of human
depression including self-care diﬃculties and despair behavior. An
increase in the immobility time in the FST and TST has been
considered as an index reﬂecting the despair behavior in mice
(Castagné et al., 2011). Also, a decrease in the grooming activity time
Fig. 3. Eﬀects of diﬀerent housing conditions and GBP treatments on the percent of open arm time (A) and percent of open arm entries (B) in the EPM. Values are presented as mean ±
S.E.M, n=7. **P < 0.01 and ***P < 0.001 compared to control SC mice, ##P < 0.01 compared to control IC mice.
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Fig. 4. Eﬀects of diﬀerent housing conditions as well as acute and chronic administration of GBP (1, 3 and 5 mg/kg) on the recorded parameters in the OFT: The time spent in the
central zone (A), the distance moved (horizontal activity) (B) and number of rearings (vertical activity) (C). Values are expressed as the mean ± S.E.M, n=7. ***P < 0.001 compared with
SC control group, ##P < 0.01 and ###P < 0.001 compared with the IC control group.
Fig. 5. Eﬀects of diﬀerent housing conditions and also acute and chronic administration of GBP (1, 3 and 5 mg/kg) on grooming activity time in the splash test. Values are expressed as
the mean ± S.E.M, n=7. ***P < 0.001 compared with SC control group and ##P < 0.01 compared with the IC control mice.
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in the splash test has recently been reported as an appropriate index to
evaluate the motivation state in both mice and rats (Surget et al., 2008;
Willner, 2005). There are pieces of evidence suggesting that GBP
possesses therapeutic properties in patients with unipolar and bipolar
disorders and improved mood status in epileptic patients (Dimond
et al., 1996; Piedad et al., 2012). In this study, our results demon-
strated that administration of both acute and chronic doses of GBP
reversed the SIS-induced depressive-like behaviors in IC mice while the
same treatments did not alter the behavior of SC animals. Acute (and
not chronic) treatment with GBP reduced the immobility time in the
FST and TST indicating that GBP is able to decrease despair behavior
in IC mice. Also, both acute and chronic GBP increased the grooming
activity time in the splash test suggesting that GBP promotes self-care
behavior in IC animals. Using FST, the antidepressant-like eﬀect of
GBP on non-stressed rats was reported in a recent study and similar to
our results the authors observed that the eﬀect of GBP appeared after
21 days of chronic treatment (Czubak et al., 2008). Anxiety is also a
prevalent comorbid disorder in people suﬀering from seizure disorders
and there are numerous ways anxiety may be associated with epilepsy
(for review see Goldstein and Harden (2000)).
Evidence from numerous clinical and preclinical studies indicate
that GBP has anxiolytic eﬀects (Perucca and Mula, 2013). In this study,
we showed that both acute and chronic GBP is able to modulate the
SIS-induced anxiety-like behaviors in the HBT and OFT as well as EPM
while such eﬀects were not observed in SC animals. In the OFT, IC mice
exhibited hyper-locomotion (increase in both vertical and horizontal
activity) along with a decrease in the time spent in the central zone of
apparatus indicating increased anxiety-like behaviors in response to a
novel environment (Kulesskaya and Voikar, 2014). Administration of
GBP reversed the anxiety -like behaviors and normalized the hyper
locomotion in IC mice as indicated by an increase in the percentage of
entries and spent time in the open arms in the EPM. Gabapentin also
reversed the anxiety-like behavior of IC mice in the HBT by increasing
the number of head-dips as an index of emotional response relevant to
anxiety (Takeda et al., 1998).
Although the exact mechanism(s) through which GBP exerts its
therapeutic eﬀects is not clear, it has been reported that this drug
modulates the high voltage-gated calcium channels through binding to
the α2-δ subunit. Accumulating evidence suggests that therapeutic
eﬀects of GBP are associated with modulation of excitatory neuro-
transmission (Sills, 2006). In this regard, recent studies showed that
GBP eﬀectively prevents hyper-excitability following cortical damage in
neonatal mice and protects against epileptiform activity in adulthood
(Andersen and Teicher, 2008; Noebels et al., 2012). Similar results
were reported by Rossi and colleagues indicating that GBP exerts
protective eﬀects against neuronal damages induced by lithium-pilo-
carpine seizures (Rossi et al., 2013). In this respect, previous research
has shown that while early SIS enhances excitatory neurotransmission
(Whitaker et al., 2013), it also diminishes the activity of inhibitory
neural systems (Matsumoto et al., 2007). Thus, the modulatory eﬀects
of GBP may be associated with the attenuation of excitatory conditions
in the brain. Additionally, the results of our study revealed that GBP
exerts its antidepressant-like eﬀect mainly by an increase in the
climbing activity and not swimming time in the FST. It is well
documented that climbing activity in the FST is mainly associated with
an increase in the adrenergic neurotransmission indicating that the
antidepressant-like eﬀect of GBP is partly mediated by the adrenergic
system (Detke et al., 1995; Schramm et al., 2001). In this case, GBP
failed to produce an antidepressant-like eﬀect when animals were pre-
treated by propranol (a beta adrenergic receptor antagonist) (data not
shown). Surprisingly, recent research has shown that GBP eﬀectively
alters the adrenergic and glutamatergic neurotransmission in the locus
coeleurus (LC), a brain structure disrupted in the depressed patients,
and plays a key role in the regulation of emotions and mood (Bernard
Fig. 6. Eﬀects of diﬀerent housing conditions (SC and IC) with acute and chronic administration of GBP (1, 3 and 5 mg/kg) on the duration of the attacks in resident-intruder test:
Values are expressed as the mean ± S.E.M, n=7. ***P < 0.001 compared to SC control group, ###P < 0.001 compared to IC control counterpart.
Fig. 7. Eﬀects of SC and IC and also acute or chronic administration of GBP (1, 3 and 5 mg/kg) on the immobility time is FST. Values are expressed as the mean ± S.E.M, n=7. **P <
0.01 compared with SC control group and ##P < 0.01 compared with the IC control counterpart.
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et al., 2011; Suto et al., 2014).
In regards to the anti-epileptic properties of GBP, higher doses of
acute GBP produced anticonvulsant eﬀects in SC mice while lower
doses exerted the same eﬀects in the IC mice. Although early SIS
increased the susceptibility of adult IC mice to the PTZ, both acute and
chronic administration of GBP reversed this eﬀect to a greater extent.
Similar treatment had no eﬀect on the seizure activity in the SC mice
indicating that sub-eﬀective doses of GBP in the SC mice (physiological
conditions) exerts potent anticonvulsant eﬀects in the IC mice (chronic
stress conditions). Our results were in line with recent ﬁndings
reporting the protective eﬀects of GBP against detrimental eﬀects of
seizure activity mostly during brain development (Cilio et al., 2001;
Goldstein and Harden, 2000). In addition, we found that the admin-
istration of GBP from adolescence (PND: 28) to adulthood (PND: 50)
produced no adverse eﬀects in SC mice. Also, we did not observe
behaviors such as aggression, anxiety, motor function and seizure
activity in the SC mice indicating that GBP is a safe drug when
administered chronically during developmental stages of the brain.
Aggression and violent behavior were also reported in people with
seizure disorders (Kanner, 2004; Mori et al., 2014). Our results
demonstrated that GBP eﬀectively succeeded to mitigate the oﬀensive
and aggressive behaviors of IC mice in the resident-intruder test. It has
been well accepted that SIS induces aggressiveness in rodents (Toth
et al., 2012). As it is believed that GBP modulates the neurotransmis-
sion mostly under excitatory conditions, it is possible that the
modulatory eﬀects of GBP on the behavioral proﬁle of IC mice are
related to its eﬀect against hyper-excitation following early SIS. In
consistent with our results, Cilio et al. found that acute or daily
administration of GBP had no eﬀect on the cognitive abilities of
animals in all ages and also GBP showed protective eﬀects against
kainite-induced seizures (an hyper-excitation condition) and aggres-
siveness in animals (Cilio et al., 2001).
It is important to note that early SIS has a great negative eﬀect on
diﬀerent neurotransmission systems, and is able to induce a variety of
behavioral abnormalities in rodents. In this regard, our recent studies
showed that SIS is able to enhance excitatory neurotransmission
through N-Methyl-D-aspartate (NMDA) receptors and nitrergic system.
These eﬀects of SIS on excitatory neurotransmission are associated
with behavioral abnormalities and increased seizure susceptibility in
rodents (Amiri et al., 2016; Haj-Mirzaian et al., 2016). Furthermore,
recent studies have reported that early SIS is able to suppress the
inhibitory neurotransmission through the downregulation of neuro-
steroid biosynthesis, which results in GABAergic neurotransmission
deﬁcits (Agís-Balboa et al., 2007; Pibiri et al., 2008). In this regard,
Matsumoto and colleagues have reported that dysfunction in neuro-
steroid biosynthesis is associated with aﬀective behavioral deﬁcits and
susceptibility to seizure in socially isolated mice (Matsumoto et al.,
2003, 2007). Thus, both excitatory and inhibitory neurotransmission
are aﬀected by SIS and play a role in the pathophysiology of behavioral
deﬁcits and increased seizure susceptibility in SIS rodents.
5. Conclusion
Taken together, in this study we found that chronic administration
of GBP during adolescence not only had no adverse eﬀect on the
behavioral proﬁle of SC mice but also reversed the seizure susceptibility
and psychiatric comorbidities in IC mice. Results of this study provided
preliminary evidence that GBP (at lower doses than therapeutic dose)
despite having anti-epileptic properties also possesses protective eﬀects
against long-term consequences of psychological stress. In future
studies, we are interested in investigating through which underlying
mechanisms GBP exerts the protective eﬀects against negative con-
sequences of early SIS.
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